Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.

[1]  Allan Linneberg,et al.  Respiratory allergy caused by house dust mites: What do we really know? , 2015, The Journal of allergy and clinical immunology.

[2]  D. Bernstein,et al.  Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. , 2015, The Journal of allergy and clinical immunology.

[3]  V. Backer,et al.  SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[4]  M. Blaiss,et al.  A comparative analysis of symptom and medication scoring methods used in clinical trials of sublingual immunotherapy for seasonal allergic rhinitis , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[5]  G. Canonica,et al.  Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. , 2014, The Journal of allergy and clinical immunology.

[6]  P. Demoly,et al.  Rhinitis , sinusitis , and upper airway disease Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis , 2016 .

[7]  J. Bousquet,et al.  Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. , 2014, Allergy.

[8]  J. Bousquet,et al.  Sublingual immunotherapy: World Allergy Organization position paper 2013 update , 2014, The World Allergy Organization journal.

[9]  D. Bernstein,et al.  Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[10]  T. Casale,et al.  An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. , 2013, The Journal of allergy and clinical immunology.

[11]  W. Lumry,et al.  Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[12]  T. Casale,et al.  Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. , 2013, The Journal of allergy and clinical immunology.

[13]  S. Durham,et al.  Efficacy and safety of the SQ‐standardized grass allergy immunotherapy tablet in mono‐ and polysensitized subjects , 2013, Allergy.

[14]  T. Casale,et al.  Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. , 2012, The Journal of allergy and clinical immunology.

[15]  S. Durham,et al.  Rhinitis , sinusitis , and upper airway disease SQ-standardized sublingual grass immunotherapy : Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial , 2012 .

[16]  M. Yılmaz,et al.  Effect of One-Year Subcutaneous and Sublingual Immunotherapy on Clinical and Laboratory Parameters in Children with Rhinitis and Asthma: A Randomized, Placebo-Controlled, Double-Blind, Double-Dummy Study , 2011, International Archives of Allergy and Immunology.

[17]  K. Hörmann,et al.  Allergen-specific immunotherapy: which outcome measures are useful in monitoring clinical trials? , 2011, Immunology and allergy clinics of North America.

[18]  M. Blaiss,et al.  Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. , 2011, The Journal of allergy and clinical immunology.

[19]  H. Riechelmann,et al.  Efficacy and Safety of a Glutaraldehyde-Modified House Dust Mite Extract in Allergic Rhinitis , 2010, American journal of rhinology & allergy.

[20]  S. Vieths,et al.  Sub‐lingual Immunotherapy: World Allergy Organization Position Paper 2009 , 2009, Allergy.

[21]  G. Viegi,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 * , 2008, Allergy.

[22]  E. Valovirta,et al.  The voice of the patients: allergic rhinitis is not a trivial disease , 2008, Current opinion in allergy and clinical immunology.

[23]  J Bousquet,et al.  Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce , 2007, Allergy.

[24]  M. Kogevinas,et al.  Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I , 2007, Allergy.

[25]  G. Canonica,et al.  Review article: Efficacy of desloratadine in the treatment of allergic rhinitis: a meta‐analysis of randomized, double‐blind, controlled trials , 2007, Allergy.

[26]  Ulrich Meier,et al.  A note on the power of Fisher's least significant difference procedure , 2006, Pharmaceutical statistics.

[27]  S. Durham,et al.  Prevalence and rate of diagnosis of allergic rhinitis in Europe , 2004, European Respiratory Journal.

[28]  A. Dirksen,et al.  The link between allergic rhinitis and allergic asthma: A prospective population‐based study. The Copenhagen Allergy Study , 2002, Allergy.

[29]  Bénédicte Leynaert,et al.  Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey , 2002, BMJ : British Medical Journal.

[30]  N. Rege,et al.  ICH Harmonised Tripartite Guideline: guideline for good clinical practice. , 2001, Journal of postgraduate medicine.

[31]  A. Buist,et al.  Validation of a standardized version of the Asthma Quality of Life Questionnaire. , 1999, Chest.

[32]  W. Pichler,et al.  Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity , 1997, Allergy.

[33]  D. Rubin.  Multiple imputation for nonresponse in surveys , 1989 .

[34]  Domján Andrea,et al.  World Medical Association Declaration of Helsinki (WMA) - Ethical principles for medical research involving human subjects , 2014 .

[35]  J. Mullol,et al.  Placebo effect in clinical trials involving patients with allergic rhinitis. , 2011, Journal of investigational allergology & clinical immunology.

[36]  D. Bernstein,et al.  Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. , 2011, The Journal of allergy and clinical immunology.

[37]  L. Klimek,et al.  Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. , 2009, The Journal of allergy and clinical immunology.